![PDF] Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar PDF] Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/2-Table1-1.png)
PDF] Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease - Kidney International The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease - Kidney International](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2043452107/2056081035/gr1.jpg)
The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease - Kidney International
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan](https://www.ccij-online.org/articles/2019/8/5/images/ClinCancerInvestigJ_2019_8_5_177_269264_t3.jpg)
The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan
PLOS ONE: Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease
![UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) - Bird - 2009 - UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) - Bird - 2009 -](https://onlinelibrary.wiley.com/cms/asset/ffecafce-1521-4793-a94e-a59e10701706/bjh_7807_f1.gif)
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) - Bird - 2009 -
![Evolution of kappa, lambda light chain level and kappa/lambda ratio (A)... | Download Scientific Diagram Evolution of kappa, lambda light chain level and kappa/lambda ratio (A)... | Download Scientific Diagram](https://www.researchgate.net/profile/Benoit-Brilland/publication/298484007/figure/fig2/AS:340336573468698@1458153970403/Evolution-of-kappa-lambda-light-chain-level-and-kappa-lambda-ratio-A-and-liver.png)
Evolution of kappa, lambda light chain level and kappa/lambda ratio (A)... | Download Scientific Diagram
![Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease](https://sjkdt.org/articles/2016/27/1/images/SaudiJKidneyDisTranspl_2016_27_1_9_174046_b1.jpg)
Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease
![The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan The diagnostic value of kappa/lambda ratios determined by immunohistochemistry in the differentiation of plasma cell myeloma from reactive plasmacytosis Shafieno Y, Izadi B, Khazaei S, Foroughikia M, Hookari S, Nazemi S, Tarlan](https://www.ccij-online.org/articles/2019/8/5/images/ClinCancerInvestigJ_2019_8_5_177_269264_t4.jpg)